These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

407 related articles for article (PubMed ID: 27844413)

  • 1. Relationship between circulating anti-thyroglobulin antibodies (TgAb) and tumor metabolism in patients with differentiated thyroid cancer (DTC): prognostic implications.
    Morbelli S; Ferrarazzo G; Pomposelli E; Pupo F; Pesce G; Calamia I; Fiz F; Clapasson A; Bauckneht M; Minuto M; Sambuceti G; Giusti M; Bagnasco M
    J Endocrinol Invest; 2017 Apr; 40(4):417-424. PubMed ID: 27844413
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correlation of 18F-FDG PET/CT findings with histopathological results in differentiated thyroid cancer patients who have increased thyroglobulin or antithyroglobulin antibody levels and negative 131I whole-body scan results.
    Ozkan E; Aras G; Kucuk NO
    Clin Nucl Med; 2013 May; 38(5):326-31. PubMed ID: 23486319
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Utility of 8F-FDG PET/CT in well differentiated thyroid carcinoma with high serum antithyroglobulin antibody.
    Kingpetch K; Pipatrattana R; Tepmongkol S; Sirisalipoch S; Chaiwatanarat T
    J Med Assoc Thai; 2011 Oct; 94(10):1238-44. PubMed ID: 22145510
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fluorodeoxyglucose PET/CT in patients with differentiated thyroid cancer and elevated thyroglobulin after total thyroidectomy and (131)I ablation.
    Salvatore B; Paone G; Klain M; Storto G; Nicolai E; D'Amico D; Della Morte AM; Pace L; Salvatore M
    Q J Nucl Med Mol Imaging; 2008 Mar; 52(1):2-8. PubMed ID: 17538522
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic significance of FDG PET/CT on the follow-up of patients of differentiated thyroid carcinoma with negative 131I whole-body scan and elevated thyroglobulin levels: correlation with clinical and histopathologic characteristics and long-term follow-up data.
    Vural GU; Akkas BE; Ercakmak N; Basu S; Alavi A
    Clin Nucl Med; 2012 Oct; 37(10):953-9. PubMed ID: 22899202
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of Thyroglobulin Doubling Time in Differentiated Thyroid Cancer and Its Relationship with Demographic-Histopathologic Risk Factors and
    Araz M; Soydal Ç; Özkan E; Akkuş P; Nak D; Küçük NÖ; Kır KM
    Cancer Biother Radiopharm; 2021 Jun; 36(5):425-432. PubMed ID: 32379488
    [No Abstract]   [Full Text] [Related]  

  • 7. The role of 18F-FDG PET/CT in the follow-up of well-differentiated thyroid cancer with negative thyroglobulin but positive and/or elevated antithyroglobulin antibody.
    Liu Y
    Nucl Med Commun; 2016 Jun; 37(6):577-82. PubMed ID: 26813991
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk factors and stratification for recurrence of patients with differentiated thyroid cancer, elevated thyroglobulin and negative I-131 whole-body scan, by restaging
    Okuyucu K; Ince S; Alagoz E; Emer O; San H; Balkan E; Ayan A; Meric C; Haymana C; Acıkel C; Gunalp B; Karacalioglu AO; Arslan N
    Hell J Nucl Med; 2016; 19(3):208-217. PubMed ID: 27824959
    [TBL] [Abstract][Full Text] [Related]  

  • 9.
    Liu J; Liu B; Yu Y; Chao F; Liu Y; Han X
    Hell J Nucl Med; 2018; 21(1):24-27. PubMed ID: 29550843
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Recovery test or immunoradiometric measurement of anti-thyroglobulin autoantibodies for interpretation of thyroglobulin determination in the follow-up of different thyroid carcinoma].
    Zöphel K; Wunderlich G; Liepach U; Koch R; Bredow J; Franke WG
    Nuklearmedizin; 2001 Oct; 40(5):155-63. PubMed ID: 11727628
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recurrence detection in differentiated thyroid cancer patients with elevated serum level of antithyroglobulin antibody: special emphasis on using (18)F-FDG PET/CT.
    Seo JH; Lee SW; Ahn BC; Lee J
    Clin Endocrinol (Oxf); 2010 Apr; 72(4):558-63. PubMed ID: 19744107
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The additive clinical value of 18F-FDG PET/CT in defining the recurrence of disease in patients with differentiated thyroid cancer who have isolated increased antithyroglobulin antibody levels.
    Ozkan E; Soydal C; Araz M; Aras G; Ibis E
    Clin Nucl Med; 2012 Aug; 37(8):755-8. PubMed ID: 22785502
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of the usefulness of positron emission tomography with [18F]fluorodeoxylglucose performed to detect non-radioiodine avid recurrence and/or metastasis of differentiated thyroid cancer - a preliminary study.
    Kolodziej M; Saracyn M; Lubas A; Brodowska-Kania D; Mazurek A; Dziuk M; Dymus J; Kaminski G
    Nucl Med Rev Cent East Eur; 2021; 24(2):63-69. PubMed ID: 34382670
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationship between serum thyroglobulin and 18FDG-PET/CT in 131I-negative differentiated thyroid carcinomas.
    Giovanella L; Ceriani L; De Palma D; Suriano S; Castellani M; Verburg FA
    Head Neck; 2012 May; 34(5):626-31. PubMed ID: 21850699
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 18F-FDG-PET/CT in Patients Affected by Differentiated Thyroid Carcinoma with Positive Thyroglobulin Level and Negative 131I Whole Body Scan. It's Value Confirmed by a Bicentric Experience.
    Bertagna F; Albano D; Bosio G; Piccardo A; Dib B; Giubbini R
    Curr Radiopharm; 2016; 9(3):228-234. PubMed ID: 27210819
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Postoperative fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography: an important imaging modality in patients with aggressive histology of differentiated thyroid cancer.
    Nascimento C; Borget I; Al Ghuzlan A; Deandreis D; Hartl D; Lumbroso J; Berdelou A; Lepoutre-Lussey C; Mirghani H; Baudin E; Schlumberger M; Leboulleux S
    Thyroid; 2015 Apr; 25(4):437-44. PubMed ID: 25633259
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Value of the negative PET-FDG in the middle term follow-up of differentiated thyroid cancer in patients with negative 131 I-Na scan and elevated thyroglobulin serum levels.
    Pachón-Garrudo VM; Cuenca-Cuenca JI; Ruiz-Franco-Baux J; Borrego-Dorado I; Tirado-Hospital JL; Navarro-González E; Vázquez-Albertino R
    Rev Esp Med Nucl Imagen Mol; 2012; 31(6):315-21. PubMed ID: 23084014
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Diagnostic Value of
    Bang JI; Park S; Kim K; Seo Y; Chong A; Hong CM; Choi M; Lee SW; Oh SW
    Thyroid; 2023 Oct; 33(10):1224-1236. PubMed ID: 37597200
    [No Abstract]   [Full Text] [Related]  

  • 19. [Patients treated for differentiated thyroid cancer with negative 131I whole-body scans and elevated thyroglobulin levels: a possible course].
    Gutiérrez Cardo AL; Rodríguez Rodríguez JR; Borrego Dorado I; Navarro González E; Tirado Hospital JL; Vázquez Albertino R
    Rev Esp Med Nucl; 2007; 26(3):138-45. PubMed ID: 17524307
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnostic accuracy of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in differentiated thyroid cancer patients with elevated thyroglobulin and negative (131)I whole body scan: evaluation by thyroglobulin level.
    Na SJ; Yoo IeR; O JH; Lin C; Lin Q; Kim SH; Chung SK
    Ann Nucl Med; 2012 Jan; 26(1):26-34. PubMed ID: 21971605
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.